Health Secretary Robert F. Kennedy Jr. has recently scrapped funding for mRNA vaccine research, prompting concerns that the U.S. isn’t prepared for future pandemics or public health crises.
Jerome Adams, who served as surgeon general under Trump, expressed disappointment, stating, “I tried to be objective about HHS’s current actions, but honestly, this decision could cost lives.” He emphasized the potential of mRNA technology, arguing it has implications beyond just vaccines, and highlighted that the rapid rollout of vaccines saved many lives.
The initial Covid-19 mRNA vaccines by Pfizer and Moderna hit the market in 2021, remarkably just a year after the virus emerged. Typically, vaccine development spans several years, but the urgency and funding from the Trump administration labeled this project as Operation Warp Speed.
This technology has proven to be safe and effective, playing a crucial role in ending the pandemic. Experts believe that mRNA could transform how we tackle evolving pathogens, particularly avian flu, due to its adaptable nature.
Kennedy’s recent announcement included a cancellation of a $500 million contract linked to mRNA vaccine research. He indicated that the agency would shift focus to methods that boast “better safety records.”
Public health specialists note that reviews of millions of mRNA vaccine doses worldwide show few adverse effects. Jeff Coller, a professor at Johns Hopkins University, remarked that this decision could slow biomedical research, sending a message that investing in mRNA technology might be unwise.
Jennifer Nuzzo, a professor of epidemiology at Brown University, voiced her concerns, calling the cancellations a threat to national security. She emphasized that diminishing such research indicates a lack of commitment to preparing for potential future biological threats.
“When we take these options off the table, we essentially signal to adversaries that we’re not serious about defending ourselves,” she explained, adding that such a stance could limit future medical innovations, including cancer treatments.
mRNA vaccines work by instructing cells to make specific proteins found on viruses, prompting the immune system to recognize and fight them off. Nuzzo pointed out that a similar approach might eventually be used for cancer vaccination, given that cancer cells have unique genetic signatures.
While the discussed contract cancellations don’t specifically target cancer research, they may create uncertainty among researchers, potentially impacting related job markets. Michael Osterholm, a prominent figure in infectious disease research, echoed these sentiments, indicating that investors might hesitate with mRNA technology due to this shift.
Kennedy has long been skeptical of vaccines, particularly mRNA ones. In 2021, he erroneously labeled the mRNA Covid-19 vaccine as “the deadliest vaccine ever,” and has faced pressure from anti-vaccine factions for not doing enough to dismantle the presence of these vaccines.
He also criticized the FDA when it approved a new version of the Moderna Covid-19 vaccine. In a recent video, Kennedy wrongly suggested that mRNA vaccines can’t safeguard against respiratory viruses, claiming they become ineffective with mutations.
Following his announcement, public health experts called on Congress to reinstate funding for mRNA vaccine research, with some labeling the move as an “assault” on federal vaccination policies. Robert Steinbrook, director of a public health group, stated that the mRNA platform is vital for rapid vaccine development in emergencies.
Nonetheless, the complete implications of Kennedy’s decisions remain unclear. A spokesperson for Moderna indicated unawareness of the newly cancelled award, noting it was previously scrapped in May in connection to an avian flu vaccine. Gritstone Bio, another firm linked to canceled contracts, ceased operations this year after declaring bankruptcy. A representative from Tiva Bio expressed surprise at the termination of their contract, as it involved treatment rather than a vaccine and did not utilize mRNA technology, but rather RNA interference, a method approved by the FDA in 2018.
